9.09% -0.085

Hoth Therapeutics Inc (HOTH)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Hoth Therapeutics Inc

(646)756-2997

590 MADISON AVENUE, NEW YORK, NY

Prossima data di guadagno

Ultimi documenti SEC

HOTH's Discussions on Twitter

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2019-10-15	Iniziato	The Benchmark Company	Speculative Buy

Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie

Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie

Monopar Therapeutics' (MNPR) MNPR-101-Zr Shows Promising Tumor Targeting in Early Clinical Trial - BP Journal

Hoth Therapeutics Inc (HOTH) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Market Watch Highlights: Hoth Therapeutics Inc (HOTH) Ends on an Upturn Note at 1.12 - The Dwinnex

Hoth Therapeutics Inc [HOTH] Stock bought by Insider Knie Robb for $16750.0 - Knox Daily

AstraZeneca (NASDAQ: AZN) Stock Dips on Lung Cancer Drug Trial Setback - ABBO News

Relay Therapeutics Shows Promising Results with RLY-2608 in Breast Cancer Study - BP Journal

Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance - BP Journal

Hoth Therapeutics Inc: Rising -68.55% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle

Are Hoth Therapeutics Inc’shares a good deal? - US Post News

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - MSN

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - Zacks Investment Research

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - Yahoo Finance

Hoth Therapeutics (NASDAQ: HOTH) Stock Skyrockets Following Approval of HT-001 Phase 2a Human Trials - ABBO News

Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Hoth Therapeutics ($HOTH) Advances to Phase 2a Trials with New Skin Toxicity Treatment - BP Journal

Hoth Therapeutics Inc (HOTH) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle

Gold Moves Higher; Science Applications International Posts Upbeat EarningsChargePoint Hldgs (NYSE:CHPT) - Benzinga

Hoth Therapeutics Reports Favorable Results for First-of-Its-Kind HT-001 Treatment of a Patient - MarketWatch

Dow Tumbles 1%; US Crude Oil Stocks FallSify Technologies (NASDAQ:SIFY) - Benzinga

HOTH’s valuation metrics: A comprehensive analysis - US Post News

Hoth reports rapid symptom relief in cancer treatment - Investing.com India

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial - StockTitan

US Stocks Edge Higher; Jobless Claims Fall To 227,000 - Benzinga

Hoth reports rapid symptom relief in cancer treatment - Investing.com

Hoth Therapeutics jumps as skin toxicity drug shows promise in one patient - XM

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 - StockTitan

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 - PR Newswire

Atara Biotherapeutics (ATRA) Secures Strategic Investments to Advance T-cell Immunotherapy Innovations - BP Journal

SPAR Group to Go Private in $2.50 Per Share Buyout by Highwire Capital - BP Journal

XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal

Applied DNA Sciences Inc. (NASDAQ: APDN): Expanding Horizons in DNA Technology and Clinical Testing - BP Journal

Hoth Therapeutics Inc (HOTH) rating initates by The Benchmark Company - Knox Daily

Hoth Therapeutics shares upgraded by EF Hutton on HT-001 potential - Investing.com

Hoth Therapeutics assumed with a Buy at EF Hutton - TipRanks

Titan Pharmaceuticals (TTNP) Announces Strategic Merger with KE Sdn. Bhd. - BP Journal

Hoth Therapeutics CEO purchases $16,750 in company stock - Investing.com

Hoth Therapeutics Inc (HOTH) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle

Hoth Therapeutics CEO purchases $16,750 in company stock By Investing.com - Investing.com Australia

ARCA Biopharma (ABIO) Announces Special Dividend Amid Merger with Oruka Therapeutics - BP Journal

Hoth Therapeutics Announces Positive Preclinical End Point Resul - GuruFocus.com

Hoth Therapeutics Announces Positive Final Results from 14-day P - GuruFocus.com

Hoth Therapeutics Inc (HOTH)’s Day in Review: Closing at 0.62, Up by 2.00 - The Dwinnex

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from HC Wainwright - Defense World

FDA Loophole Raises Concerns About Oncology Drug Approvals and More - OBR Oncology

Hoth and Aronnax partner for HT-KIT cancer therapy development - Yahoo Finance

Hoth and Aronnax partner for HT-KIT cancer therapy development - Pharmaceutical Technology

Hoth Therapeutics Inc (HOTH) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Hoth Therapeutics advances HT-KIT cancer drug study By Investing.com - Investing.com Canada

Hoth Therapeutics advances HT-KIT cancer drug study By Investing.com - Investing.com India

Hoth Therapeutics advances HT-KIT cancer drug study - Investing.com

Hoth Therapeutics advances HT-KIT cancer drug study By Investing.com - Investing.com Australia

Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a HOTH